Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

ACE2 receptor is responsible for the wide host range of SARS-CoV-2

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is thought to have a zoonotic origin, perhaps originating in a bat coronavirus with an unknown intermediate host. It is not only very infectious but has been found to infect a wide range of mammals, including dogs, cats, ferrets, hamsters, and minks, besides non-human primates. This range may be still higher, claims a recent preprint that appeared in January 2021 on the bioRxiv server.

6 Jan 2021

Is one-dose COVID-19 vaccination better than two?

A recent study published on the preprint server medRxiv in December 2020 reflects on the possibility of using a single-dose vaccine regimen to accomplish large-scale vaccination as early as possible.

6 Jan 2021

More stringent measures may be needed to control new SARS-CoV-2 B.1.1.7 variant in England

Researchers in the UK have conducted a comprehensive epidemiologic analysis of the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant in an effort to learn more about the expanded range and frequency of coronavirus disease 2019 (COVID-19) cases in England.

6 Jan 2021

In-silico modeling provides new understanding of immune response to SARS-CoV-2

The COVID-19 pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has crippled global healthcare systems and triggered an economic crisis in many countries. The pandemic is not showing signs of a slowdown even in 2021 with a new and more infectious variant of the virus wreaking havoc in the UK and many other parts of the world.

6 Jan 2021

Study shows durable specific humoral immunity against SARS-CoV-2 after mild or asymptomatic infection

As a part of the COMMUNITY (COVID-19 Immunity) study, researchers from Sweden reveal long-lasting IgG neutralizing antibody response against spike glycoprotein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the vast majority of convalescent individuals – even after asymptomatic or mild infection. Their results are currently available on medRxiv* preprint server.

6 Jan 2021

Neutralization antibodies affected by only a few mutations to the SARS-CoV-2 receptor-binding domain

In a recent bioRxiv* preprint paper, US researchers mapped in detail how mutations to the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) affected antibody binding in convalescent human serum – and revealed that it is influenced by mutations at only a handful of dominant epitopes.

6 Jan 2021

NIAID set to conduct large monoclonal SARS-CoV-2 antibody clinical trial

A large clinical trial, known as the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-2), is set to take place, which aims to test monoclonal antibody efficacy and safety in people who have mild or moderate COVID-19.

6 Jan 2021

Vitamin D supplementation found to reduce COVID-19-related mortality, says study

Researchers have shown that prescribing vitamin D supplementation to COVID-19 patients seems to decrease the mortality rate, the severity of the disease, and serum levels of inflammatory markers.

6 Jan 2021

Disulfide-reducing agents demonstrate potential antiviral activity against SARS-CoV-2

Researchers recently demonstrated that chemical agents capable of reducing disulfide (S-S) bonds can be potentially used as antiviral drugs against SARS-CoV-2, the causative pathogen of COVID-19.

6 Jan 2021

Modified Vaccinia Ankara model vaccine prevents COVID-19 in transgenic mice study

A new study shows the effectiveness of a novel recombinant vaccinia virus that expresses modified SARS-CoV-2 spike antigen, in preventing the replication of the virus in the respiratory tract of transgenic mice, and to prevent lethal disease.

6 Jan 2021

Are SARS-CoV-2 antibodies associated with disease enhancement?

As SARS-CoV-2 continues to wreak its havoc, antibodies that neutralize the virus and protect against infection have become an important focus of research. However, there is a concern as to whether these antibodies can actually enhance the disease.

6 Jan 2021

Researchers claim SARS-CoV-2 B.1.1.7 variant likely to become globally dominant

The new variant of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) detected in England replicates more than two times faster than the earlier strains. This replication advantage promises to make it the dominant global variant very shortly. This finding comes from a startling preprint that appeared on the medRxiv* server in December 2020.

6 Jan 2021

Glycyrrhizin in licorice root neutralizes SARS-CoV-2 in vitro by inhibiting the main protease Mpro

In a recent bioRxiv* preprint paper, researchers from Germany analyzed aqueous licorice root extract for its neutralizing activity against SARS-CoV-2 in vitro. They identified glycyrrhizin, the primary active ingredient in the root, and revealed the underlying mechanism of viral neutralization.

5 Jan 2021

One-third of COVID-19 survivors manifest neurological problems

In a longitudinal study recently published on the preprint server medRxiv*, Andrea Pilotto et al. find that one-third of COVID-19 infection survivors have long-term neurological manifestations after hospitalization.

5 Jan 2021

COVID-19 vaccine hesitancy in UK varies significantly between population subgroups

Researchers investigating attitudes towards vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among the UK population have found that, overall, most people were willing to accept a vaccine.

5 Jan 2021

COVID-19 vaccination in UK may not lead to relaxation of control measures

Researchers have warned that early relaxation of coronavirus disease 2019 (COVID-19) control measures in the UK could lead to pronounced waves of further infection with the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

5 Jan 2021

SARS-CoV-2 infected alveolar type-II lung cells show senescence

Using monoclonal antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and senescent markers, researchers provide evidence that virus-infected lung cells acquire characteristics of cellular senescence, which also leads to expression of proinflammatory cytokines.

5 Jan 2021

Could asymptomatic SARS-CoV-2 screening in dental practices help prevent silent transmission?

Researchers conducted a mass, asymptomatic screening of patients in dental surgeries across Scotland to assess illustrate its potential utility in curbing silent transmission.

5 Jan 2021

Copper surfaces can inactivate SARS-CoV-2 in as little as one minute, study finds

A new study by researchers at the University of Southampton, UK, has found that SARS-CoV-2 can inactivate on copper surfaces in as little as 1 minute. This is faster than the findings of previous studies in which it took as much as 4 hours before the virus was inactivated.

5 Jan 2021

Can interregional travel restrictions curb SARS-CoV-2 transmission?

A study led by Dr. Keisuke Kondo at the Research Institute of Economy, Trade and Industry, Japan, has recently developed a mathematical model to investigate the impacts of interregional mobility restriction on the transmission of SARS-CoV-2.

5 Jan 2021

Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

ACE2 receptor is responsible for the wide host range of SARS-CoV-2

Is one-dose COVID-19 vaccination better than two?

More stringent measures may be needed to control new SARS-CoV-2 B.1.1.7 variant in England

In-silico modeling provides new understanding of immune response to SARS-CoV-2

Study shows durable specific humoral immunity against SARS-CoV-2 after mild or asymptomatic infection

Neutralization antibodies affected by only a few mutations to the SARS-CoV-2 receptor-binding domain

NIAID set to conduct large monoclonal SARS-CoV-2 antibody clinical trial

Vitamin D supplementation found to reduce COVID-19-related mortality, says study

Disulfide-reducing agents demonstrate potential antiviral activity against SARS-CoV-2

Modified Vaccinia Ankara model vaccine prevents COVID-19 in transgenic mice study

Are SARS-CoV-2 antibodies associated with disease enhancement?

Researchers claim SARS-CoV-2 B.1.1.7 variant likely to become globally dominant

Glycyrrhizin in licorice root neutralizes SARS-CoV-2 in vitro by inhibiting the main protease Mpro

One-third of COVID-19 survivors manifest neurological problems

COVID-19 vaccine hesitancy in UK varies significantly between population subgroups

COVID-19 vaccination in UK may not lead to relaxation of control measures

SARS-CoV-2 infected alveolar type-II lung cells show senescence

Could asymptomatic SARS-CoV-2 screening in dental practices help prevent silent transmission?

Copper surfaces can inactivate SARS-CoV-2 in as little as one minute, study finds

Can interregional travel restrictions curb SARS-CoV-2 transmission?

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in